ALSPW Spineway SAS

2023 : high increase in turnover

2023 : high increase in turnover

Press release        Ecully, April 13, 2023 – 6 p.m.



First-quarter 2023 revenue of €2.4 million (+79%)

In thousands of euros20232022Change



as a %
Q1 revenue2,3991,342+79%

Unaudited consolidated data

Spineway has achieved a total revenue of €2.4 million as of Q1 2023, representing growth of 79% compared with Q1 2022, mainly driven by sales of Spine Innovations’ disc prostheses. Adjusted for this contribution, quarterly revenue remains robust and represents an all-time high of €1.4 million despite a temporary delay in Latin America due to regulatory procedures for the approval of new products.

The Europe area is driving growth and accounts for 57% of consolidated revenue over the quarter. Revenue amounts to €1.4 million, a 3.2-fold increase compared with the same period last year, thereby confirming the commercial strategy announced last year. The area benefits from the sales’ dynamics in France, where the ramp-up of the Distimp ranges and the contribution of the Spine Innovations ranges are paying off.

This first quarter of 2023 confirms the rollout of Spineway’s product strategy and the successful integration of Spine Innovations.

These developments, combined with R&D investments dedicated to new product lines, will help position Spineway as a leading international player in the spine sector.

Next events: July 11, 2023 – H1 2023 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR001400BVK2 - ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060




ELIGIBLE PEA PME



ALSPW





EURONEXT GROWTH




AELIUM



Investor relations



Solène Kennis



Attachment



EN
13/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : H1 2025 results - Continued improvement in results and fina...

Spineway : H1 2025 results - Continued improvement in results and financial position Press release         Ecully, July 30, 2025 – 7 p.m.   SPINEWAY H1 2025 results  Continued improvement in results and financial positionFull-year 2025 growth target confirmed In thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535Cost of sales(1,702)(2,059)Gross margin% of revenue3,87069%4,47668%Net operating expensesOf which general operating costs(5,068)(2,086)(5,246)(2,232)Of which personnel expenses(2,374)(2,685)Operating income/(loss)(1,197)(770)Fina...

 PRESS RELEASE

SPINEWAY : Résultats semestriels 2025 - Poursuite de l’amélioration de...

SPINEWAY : Résultats semestriels 2025 - Poursuite de l’amélioration des résultats et de la situation financière Communiqué de presse        Ecully, le 30 juillet 2025 –19h SPINEWAY Résultats semestriels 2025 Poursuite de l’amélioration des résultats et de la situation financièreObjectif de croissance confirmé pour l’année 2025 En milliers d'eurosComptes consolidés – Non auditésS1 2025S1 2024Chiffre d'affaires5 5736 535Coût des ventes- 1 702- 2 059Marge brute% du CA3 87069%4 47668%Coûts nets d’exploitationDont coûts de fonctionnement- 5 068- 2 086- 5 246- 2 232Dont charges de personnel-...

 PRESS RELEASE

Spineway : GMED approval for new production line dedicated to ESP pros...

Spineway : GMED approval for new production line dedicated to ESP prostheses - First production of LP-ESP intervertebral disc prostheses Press release         Ecully, July 3, 2025 – 6:30 p.m. SPINEWAY GMED approval for new production line dedicated to ESP prostheses First production of LP-ESP intervertebral disc prostheses Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has received (French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral di...

 PRESS RELEASE

SPINEWAY : Approbation du GMED pour la nouvelle ligne de production dé...

SPINEWAY : Approbation du GMED pour la nouvelle ligne de production dédiée aux prothèses ESP - 1ère production de prothèses de disque intervertébral LP-ESP Communiqué de presse          Ecully, le 3 juillet 2025 – 18h30 SPINEWAY Approbation du GMED pour la nouvelle ligne de production dédiée aux prothèses ESP 1ère production de prothèses de disque intervertébral LP-ESP Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que sa filiale Spine Innovations a reçu la validation du (Organisme notifié français) ...

 PRESS RELEASE

Spineway : Minutes of the General Meeting of June 4, 2025

Spineway : Minutes of the General Meeting of June 4, 2025 Press release         Ecully, June 6, 2025 – 6.00 p.m.   SPINEWAY Minutes of the General Meeting of June 4, 2025 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69). The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2025. The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch